GlassScriptPhysician profile
Paurush Babbar
NPI 1770826695
$140,145.57
in general payments reported to CMS, 2019-2025
38 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $375 · 2021: $1,759 · 2022: $1,286 · 2023: $8,102 · 2024: $48K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $32K · Food and Beverage: $8,560 · Travel and Lodging: $7,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,093.75 |
| Consulting Fee | $31,668.75 |
| Food and Beverage | $8,559.78 |
| Travel and Lodging | $7,685.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $136,693.09 | 2019-2025 | General - Erectile Dysfunction, Tactra, Advance Xp |
| Astellas Pharma US INC | $372.20 | 2020-2025 | Xtandi, Myrbetriq |
| Endo USA, INC. | $353.30 | 2024-2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $228.17 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $214.36 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $207.53 | 2020-2024 | Aveed, Xiaflex |
| Dendreon Pharmaceuticals LLC | $154.97 | 2020-2024 | Provenge |
| Urogen Pharma, INC. | $146.75 | 2021-2025 | Jelmyto |
| Antares Pharma, INC. | $135.24 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Axonics, INC. | $131.59 | 2020-2024 | Axonics |
| Accord Healthcare, INC. | $119.13 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $109.01 | 2021-2024 | Keytruda, Welireg, Lynparza |
| Immunitybio, INC. | $107.25 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $91.04 | 2023-2025 | Pylarify |
| Urovant Sciences INC | $89.99 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $82.89 | 2020-2022 | |
| Hollister Incorporated | $78.90 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $77.52 | 2022-2025 | |
| Acerus Pharmaceuticals Corporation | $77.13 | 2020-2022 | |
| Clarus Therapeutics INC. | $74.81 | 2021 | |
| Janssen Biotech, INC. | $70.83 | 2022-2024 | Erleada |
| Tolmar, INC. | $65.51 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $56.60 | 2024-2025 | |
| Teleflex LLC | $52.68 | 2021-2025 | Barrigel |
| Convatec INC. | $48.04 | 2022 | |
| Pfizer INC. | $43.47 | 2023-2024 | |
| Abbvie INC. | $39.45 | 2022-2023 | Botox |
| Becton, Dickinson and Company | $29.10 | 2024 | Arista Ah Flexitip |
| Allergan, INC. | $28.39 | 2021 | |
| Procept Biorobotics Corporation | $24.35 | 2024 | Aquabeam System |
| Sun Pharmaceutical Industries INC. | $20.72 | 2022 | |
| Myovant Sciences INC. | $20.04 | 2022 | |
| Olympus America INC. | $19.00 | 2025 | Itind System |
| Coloplast Corp | $18.38 | 2020 | |
| Neotract INC. | $17.89 | 2020 | |
| Ferring Pharmaceuticals INC. | $17.78 | 2025 | Adstiladrin |
| Foundation Medicine, INC. | $15.91 | 2020 | |
| Rigicon,INC. | $12.56 | 2023 | Rigi10 Malleable Penile Prosthesis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paurush Babbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.